Figueroa-Sandoval JF

Idioma: Español
Referencias bibliográficas: 18
Paginas: 79-82
Archivo PDF: 188.09 Kb.

FRAGMENTO

Estimado Editor:

La radioterapia en linfomas ha cambiado a través de los años; en 1970 se utilizaba radioterapia nodal total (basada en la anatomía 2D [ósea]); en 1995 radioterapia al campo afectado (basada en la anatomía 3D [GTV, CTV, PTV]) que incluye la extensión original de la enfermedad más el margen para considerar las limitaciones de las imágenes y los detalles del sitio de la enfermedad; en 2008 radioterapia al ganglio afectado (basada en la anatomía 3D [GTV, CTV, PTV]) que incluye la extensión original de la enfermedad con el margen, requiere PET.
También la dosis administrada de radioterapia se redujo en linfoma de Hodgkin en los decenios de 1960 a 1980; 44Gy-55Gy, y a partir de la década de 1990, 20-30 Gy.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Specht L, Yahalom J, Illidge T, Kill A, et al. Modern radiationtherapy for Hodgkin Lymphoma: field and dose guidelinesfrom international lymphoma radiation oncology group.Int J Radiat Oncol Biol Phys 2014; 89 (4): 854-62. doi:10.1016/j.ijrobp.2013.05.005.

2. Camphell B, Voss N, Pickles T, Morris J, et al. Involved-nodalradiation therapy as a component of combination therapyfor limited-stage Hodgkin lymphoma: a question of fieldsize. J Clin Oncol 2008; 26 (32): 5170-5174. doi: 10.1200/JCO.2007.15.1001.

3. Maraldo MV, Aznar MC, Vogelius I, Petersen P, et al. Involvednode radiation therapy: an effective alternative in earlystage Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys2013; 85 (4): 1057-65. doi: 10.1016/j.ijrobp.2012.08.041.

4. Patel CG, Ng AK. Involved-site radiation therapy for earlystageNLPML. Int J Radiat Oncol Biol Phys 2020; 107 (1):21-22. doi: 10.1016/j.ijrobp.2019.09.025.

5. Milgrom SA, Rechner L, Berthelsen A. The optimal useof PET/CT in the management of lymphoma patients.Br J Radiol 2021; 94 (1127): 20210470. doi: 10.1259/bjr.20210470.

6. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, et al.Role of imaging in the staging and response assessment oflymphoma: consensus of the International Conference onMalignant Lymphoma Imaging Working Group. J Clin Oncol2014; 32: 3038-3058. doi: 10.1200/JCO.2013.53.5229.

7. Radford J, Illidge T, Counsell N, Hancock B, et al. Resultsof a trial of PET-directed therapy for early-stage Hodgkin’slymphoma. N Engl J Med 2015; 372: 1598-1607. DOI:10.1056/NEJMoa1408648.

8. André M, Girinsky T, Federico M, Oumedaly R, et al.Early positron emission tomography response-adaptedtreatment in stage I and II Hodgkin lymphoma: Final resultsof the randomized EORT/LYSA/FIL H10 Trial. J Clin Oncol2017; 35 (16): 1786-1794. DOI:10.1200/JCO.2016.68.6394.

9. Herbst C, Rehan FA, Brillant C, Bohilus J, et al. Combinedmodality treatment improves tumor control and overallsurvival in patients with early stage Hodgkin’s lymphoma:a systematic review. Haematologica 2010; 95 (3): 494-500.doi: 10.3324/haematol.2009.015644.

10. Brady JL, Binkley MS, Hajj C, Chelius M, et al. Definitive radiotherapyfor localized folicular lymphoma staged by 18FFDGPET-CT: a collaborative study by ILROG. Blood 2019;133 (3): 237-245. doi: 10.1182/blood-2018-04-843540.

11. Houlihan OA, Rangaswamy G, Dunne M, Rohan C, et al.Deep inspiration breath hold versus free breathing techniquein mediastinal radiotherapy for lymphoma. BJR 2021;3(1):20200067. doi: 10.1259/bjro.20200067.

12. Zullo A, Hassan C, Ridola L, Repici A, et al. Gastric MALTlymphoma: old and new insights. Ann Gastroenterol 2014;27 (1): 27-33.

13. Illerhaus G, Kasenda B, Ihorst G, Egerer G, et al. High-dosechemotherapy with autologous haematopoietic stemcell transplantation for newly diagnosed primary CNSlymphoma a prospective single-arm, phase 2 trial. LancetHaematol 2016; 3 (8): 388-397. doi: 10.1016/S2352-3026(16)30050-3.

14. Alnahhas I, Jawish M, Alsawas M, Zukas A, et al. Autologousstem cell transplantation for primary central nervoussystem lymphoma: systematic review and meta-analysis.Clin Lymphoma Myeloma Leuk 2019; 19 (3): 129-141. doi:10.1016/j.clml.2018.11.018.

15. Goda JS, Le LW, Lapperriere NJ, Millar BA, et al. Localizedorbital mucosa-associated lymphoma tissue lymphomamanaged with primary radiation therapy: efficacy andtoxicity. Int J Radiat Oncol Biol Phys 2011; 81 (4): 659-66.doi: 10.1016/j.ijrobp.2011.03.050.

16. Baron J, Wright CM, Lee DY, Carpenter M, et al. Low–dose radiotherapy versus moderate dose radiotherapyfor the treatment of indolent orbital adnexallymphoma. Front Oncol 2021; 11: 716002. doi: 10.3389/fonc.2021.716002.

17. Kim SJ, Kim K, Kim BS, Kim CY, et al. Phase II trial of concurrentradiation and weekly cisplatin followed by VIPDchemotherapy in newly diagnosed, stage I E to II E nasalextranodal NK/T cell lymphoma. J Clin Oncol 2009; 27:6027-6032. doi: 10.1200/JCO.2009.23.8592.

18. Kim SJ, Yoon SE, Kim WS. Treatment of localized extranodalNK/T cell lymphoma nasal type: a systematic review.J. Hematol Oncol 2018; 11 (1):140-150. doi: 10.1186/s13045-018-0687-0.